STOCK TITAN

Venture firm NEA takes 22.2% stake in SpyGlass Pharma (SGP) after IPO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

SpyGlass Pharma’s major venture backer New Enterprise Associates (NEA) has disclosed a large stake following the company’s IPO. NEA 16 and NEA 17 together hold 7,392,301 shares of common stock of SpyGlass Pharma, representing 22.2% of the 33,317,414 shares outstanding as of February 9, 2026.

NEA 17 bought 937,500 shares in the IPO at $16 per share and both funds converted significant preferred stock holdings into common shares after a reverse split. The funds state the shares were acquired for investment purposes, have broad registration rights, and are subject to 180‑day IPO lock-up and market standoff agreements.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 17, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA Partners 17, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA 17 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
New Enterprise Associates 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA Partners 16, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
NEA 16 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/13/2026
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:02/13/2026
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:02/13/2026
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:02/13/2026
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
Date:02/13/2026
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:02/13/2026
Edward T. Mathers
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Edward T. Mathers
Date:02/13/2026
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:02/13/2026
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:02/13/2026
Rick Yang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Rick Yang
Date:02/13/2026
Comments accompanying signature:
This Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

How large is New Enterprise Associates’ stake in SpyGlass Pharma (SGP)?

New Enterprise Associates reports beneficial ownership of 7,392,301 SpyGlass Pharma common shares, or 22.2% of the company. This percentage is based on 33,317,414 shares outstanding as of February 9, 2026, including the IPO underwriters’ full exercise of their option.

How did NEA acquire its SpyGlass Pharma (SGP) shares?

NEA acquired SpyGlass Pharma shares through IPO purchases and prior private preferred stock investments. NEA 17 bought 937,500 IPO shares at $16 each, while earlier Series A, B, C-1, C-2 and D preferred holdings converted one-for-one into common stock immediately before the IPO closing.

What lock-up restrictions apply to NEA’s SpyGlass Pharma (SGP) shares?

Each NEA fund agreed to a 180-day lock-up starting February 5, 2026. During this period, they generally cannot sell, pledge, hedge or otherwise transfer SpyGlass common stock or related convertible securities without written consent from the IPO underwriters or the managing underwriter, subject to limited exceptions.

What registration rights does NEA have for its SpyGlass Pharma (SGP) shares?

Under a May 30, 2025 Investors’ Rights Agreement, NEA and other holders have demand, Form S-3 and piggyback registration rights. They can request S-1 offerings of at least $10 million, S-3 offerings of at least $1 million, and inclusion when SpyGlass files other eligible registration statements.

Who among NEA’s managers directly holds SpyGlass Pharma (SGP) equity?

As of February 13, 2026, Ali Behbahani directly holds options to purchase 1,522 SpyGlass common shares exercisable within 60 days. Other listed NEA managers are deemed beneficial owners through control entities, but each reporting person disclaims beneficial ownership except for shares held of record.

What is the purpose of NEA’s investment in SpyGlass Pharma (SGP)?

NEA states it acquired SpyGlass Pharma shares for investment purposes. The funds and related reporting persons may buy more or sell shares depending on market conditions and their evaluation of the business, but report no current plans for mergers, control changes or other major corporate actions.
SpyGlass Pharma, Inc.

NASDAQ:SGP

View SGP Stock Overview

SGP Rankings

SGP Latest News

SGP Latest SEC Filings

SGP Stock Data

753.31M
9.38M
Surgical & Medical Instruments & Apparatus
ALISO VIEJO